A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
Status:
Not yet recruiting
Trial end date:
2026-02-15
Target enrollment:
Participant gender:
Summary
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®)
treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary
objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive
low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first
48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives
listed in the detailed description below.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborators:
Children's Healthcare of Atlanta Children's Hospital Los Angeles